Clinical Translation of Combined MAPK and Autophagy Inhibition in RAS Mutant Cancer.

Abstract excerpt

RAS (rat sarcoma virus) mutant cancers remain difficult to treat despite the advances in targeted therapy and immunotherapy. Targeted therapies against the components of mitogen-activated protein kinase (MAPK) pathways, including RAS, RAF, MEK, and ERK, have demonstrated activity in BRAF mutant and, in limited cases, RAS mutant cancer. RAS mutant cancers have been found to activate adaptive resistance mechanisms...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Autophagy
• Share to Drug Resistance, Neoplasm
• Share to Drug Therapy, Combination